C07J 1/0022
The substituent being an oh group free esterified or etherified
Official title: {the substituent being an OH group free esterified or etherified}
C07J1/0022 (The substituent being an oh group free esterified or etherified) appears on 204 US grants and 133 published applications in this corpus.
Search patents in C07J- Granted patents
- 204
- Published applications
- 133
- Assignees
- 100
- Inventors
- 415
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 12 | 0 |
| 1978 | 12 | 0 |
| 1979 | 6 | 0 |
| 1980 | 10 | 0 |
| 1981 | 7 | 0 |
| 1982 | 7 | 0 |
| 1983 | 0 | 0 |
| 1984 | 7 | 0 |
| 1985 | 5 | 0 |
| 1986 | 0 | 0 |
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 5 | 0 |
| 1990 | 7 | 0 |
| 1991 | 5 | 0 |
| 1992 | 6 | 0 |
| 1993 | 6 | 0 |
| 1994 | 3 | 0 |
| 1995 | 7 | 0 |
| 1996 | 7 | 0 |
| 1997 | 12 | 0 |
| 1998 | 6 | 0 |
| 1999 | 5 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 4 |
| 2004 | 3 | 3 |
| 2005 | 1 | 2 |
| 2006 | 2 | 1 |
| 2007 | 0 | 4 |
| 2008 | 1 | 4 |
| 2009 | 0 | 1 |
| 2010 | 3 | 1 |
| 2011 | 4 | 3 |
| 2012 | 1 | 5 |
| 2013 | 1 | 4 |
| 2014 | 1 | 4 |
| 2015 | 2 | 6 |
| 2016 | 0 | 4 |
| 2017 | 4 | 10 |
| 2018 | 2 | 9 |
| 2019 | 3 | 7 |
| 2020 | 3 | 6 |
| 2021 | 2 | 7 |
| 2022 | 6 | 7 |
| 2023 | 8 | 8 |
| 2024 | 4 | 9 |
| 2025 | 5 | 11 |
| 2026 | 1 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- C17, C20, and C21 substituted neuroactive steroids and their methods of use16 Jun 2026US 12,655,175 B2Sage Therapeutics, Inc.
- Androstane derivatives with activity as pure or predominantly pure stimulators of SERCA2a for the treatment of heart failure23 Dec 2025US 12,503,484 B2Seismic Pharmaceuticals
- Encoded design integrated synthesis of nucleic acids, and phospholipids, and related pharmaceutical products18 Nov 2025US 12,473,247 B2
- (17-)-3-oxoandrost-4-en-17-yl dodecanoate compositions and methods of preparation and use8 Jul 2025US 12,351,600 B2
- 5 alpha dihydrotestosterone formulations and associated methods of use and treatment6 May 2025US 12,290,525 B2
- Lymph directing prodrugs24 Sep 2026US 2026/0284004 A1Monash University
- Preparation of deoxycholic acid16 Jul 2026US 2026/0200967 A1Crystal Pharma, S.A.U.
- Novel method for preparing testosterone derivatives by solid-phase synthesis25 Jun 2026US 2026/0174913 A1King Faisal Specialist Hospital & Research Centre
- Lymph directing prodrugs4 Jun 2026US 2026/0151489 A1Monash University
- Androstane Derivatives with Activity as Pure or Predominantly Pure Stimulators of SERCA2a for the Treatment of Heart Failure7 May 2026US 2026/0125415 A1Seismic Pharmaceuticals Operations LLC
Most cited
By later US patents
- Anti-estrogenic compounds and compositions119US 5,395,842 AEndorecherche, Inc. · 1995
- Neuroactive steroids of the androstane and pregnane series114US 5,925,630 ACoCensys, Inc. · 1999
- 19-Oxygenated-5.alpha.-androstanes for the enhancement of libido91US 4,071,625 ARichardson-Merrell Inc. · 1978
- Oral pharmaceutical preparation85US 4,147,783 AAkzona Incorporated · 1979
- 17-Hydroxy-steroids72US 4,898,694 A1990